Question Bank › Mid-ramp quarter: contribution has started but t

Mid-ramp quarter: contribution has started but the period only caught part of it

Calls Tested
421
Answered YES
20
Hit Rate
4.8%
rare by design

Regeneron Pharmaceuticals, Inc. (REGN) — this company's answers

NO on the Q4 2022 call 2023-02-03 C
The model's full reasoning — Q4 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了一个已经开始贡献但只部分反映在报告期内的新业务活动,并明确表示报告结果只捕捉了该贡献者的一部分,而更完整的运行率将在未来几个季度到来,这是时间问题而非赢得问题。 检查三个条件: (1) 一个可命名的、已经上线或即将上线的新贡献者。管理层是否识别了最近开始或即将开始的具体业务?例如,新合同、新设施、新产品、新客户、新收购等。 在记录中,管理层提到了几个新事物: - aflibercept 8毫克(高剂量阿柏西普)的BLA提交,预计2023年8月获批,但尚未上市,所以不是已经开始的贡献者。 - Libtayo在非小细胞肺癌的批准(2022年11月获批),但这是已经批准的,且报告期是2022年Q4,可能已经包含部分贡献,但管理层没有明确说这是部分贡献。 - Dupixent的新适应症(如prurigo nodularis、eosinophilic esophagitis)在2022年获批,但同样,这些是已经批准的,且报告期可能已经包含。 - 新的COVID抗体,但还在临床前,未开始。 - 成本刺激双特异性抗体(如PSMAxCD28)在早期数据,但还在剂量递增,未上市。 关键点:管理层是否明确说某个新业务已经开始贡献,但只部分反映在报告期内,并且未来几个季度会达到完整水平? 在电话会议中,管理层提到了“aflibercept 8毫克”的潜在上市,但那是未来,不是已经开始的。对于Libtayo,管理层说“Customer ordering has accelerated following the chemotherapy combination approval last November.” 但这是说订单加速,但并没有说报告期只包含部分贡献,且未来会更多。对于Dupixent,管理层说“we have an opportunity to reach even more patients with potential regulatory approvals in new diseases, geographies and younger populations that could add another approximately 500,000 patients globally to the biologic eligible population.” 但这是未来批准,不是已经开始的。 管理层还提到了“we are preparing for a potential U.S. launch for aflibercept 8 milligrams in late August” 这是未来。 有没有一个明确的“新贡献者”已经上线?可能指的是Libtayo的肺癌适应症,但那是2022年11月批准的,Q4报告期是10-12月,所以可能只有部分月份贡献,但管理层没有明确说“报告期只包含部分,未来会更多”这样的表述。管理层说“Early launch indicators are positive”但并没有说报告期只包含部分。 再检查是否有其他新业务,比如“Checkmate Pharmaceuticals”收购,但那是2022年完成的,可能已经整合,但管理层没有说这是部分贡献。 另一个可能:管理层提到“we expect 2023 other revenue to be slightly lower than 2022” 这不是新贡献。 所以,似乎没有明确的新业务活动已经开始贡献且只部分反映在报告期内,并且管理层明确说未来几个季度会达到完整水平。管理层谈论的更多是未来计划,而不是已经开始的。 因此,答案应为NO。

← Back to the full REGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe an identifiable piece of new business activity that has ALREADY STARTED CONTRIBUTING PARTWAY THROUGH THE REPORTED PERIOD OR IS STARTING RIGHT NOW — and make clear that the reported results captured only a PARTIAL, EARLY SLICE of it, with the fuller run-rate arriving over the next few quarters as a matter of timing rather than as a matter of winning anything further? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent timing story with all three of the following present: (1) A NAMEABLE NEW CONTRIBUTOR THAT IS ALREADY LIVE OR JUST GOING LIVE. Management identifies specific business that recently began or is beginning now — for example, a contract or program whose deliveries or billings recently started; a facility, location, line, or capacity that recently opened or is opening; a product, service, or offering that recently launched and is now selling; a customer or group of customers recently onboarded and now ramping; an acquisition recently closed and now contributing; or newly added capability now taking on its first real volume. The contributor must be described as actually transacting or commencing — real revenue, orders, shipments, output, or activity happening — not as pipeline, negotiation, or plan. (2) THE REPORTED PERIOD CAUGHT ONLY PART OF IT, AND MANAGEMENT SAYS SO. Management conveys, directly or plainly in substance, that the just-reported results include only a fraction of this contributor's normal level — because it started mid-period, is still ramping toward its intended level, or its costs arrived ahead of its revenue — so the printed numbers understate the level the business is already operating at or stepping to. (3) THE FULLER CONTRIBUTION IS A TIMING MATTER, NOT A WINNING MATTER. Management discusses the path to the fuller level in execution terms — ramp pace, onboarding, production schedules, utilization building, quarters until full contribution — with the remaining uncertainty being how fast, not whether the business exists. Management should treat this arriving contribution as meaningful to the company's trajectory, not as a minor housekeeping item. Answer NO if the new activity is only planned, signed-but-not-started, contingent on approvals or financing, or still pipeline. NO if the contributor is already fully reflected in results with no meaningful further phase-in ahead. NO if the forward story rests mainly on market recovery, demand strength, or hoped-for wins rather than on the phase-in of activity already begun. NO if the ramp described is routine, immaterial, or the company's ordinary ongoing cadence that management does not treat as changing its level of business. NO if management is chiefly explaining delays, shortfalls, or problems with a previously promised ramp. NO if the timing story appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
GPRE Green Plains Inc. Q4 2023 2024-02-07 F
TEL TE Connectivity Ltd. Q4 2023 2023-11-01 B
AFL Aflac Incorporated Q2 2023 2023-08-02 C+
CTO CTO Realty Growth, Inc. Q2 2023 2023-07-28 B
WHF WhiteHorse Finance, Inc. Q1 2022 2022-05-10 B+
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
MAS Masco Corporation Q3 2018 2018-10-30 C
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
ACHC Acadia Healthcare Company, Inc. Q4 2017 2018-02-22 C+
HTLF Heartland Financial USA, Inc. Q3 2017 2017-10-30 B+
MXL MaxLinear, Inc. Q2 2017 2017-08-08 C+
FLEX Flex Ltd. Q1 2018 2017-07-28 F
LEA Lear Corporation Q2 2017 2017-07-26 B+
DAN Dana Incorporated Q1 2017 2017-05-02 B
SHOO Steven Madden, Ltd. Q1 2017 2017-04-21 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
WTS Watts Water Technologies, Inc. Q4 2016 2017-02-10 B

How the model reasoned

SHOO · Q1 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the Schwartz & Benjamin acquisition as a new contributor that began delivering sales in the reported Q1 period ($14 million, slightly above plan), with the results capturing only its early partial slice. Management explicitly notes that the full-quarter impact will arrive in subsequent quarters (dragging gross margin more going forward), 2017 will be breakeven-to-EPS, and meaningful profit contribution starts in 2018—making the fuller run-rate a pure timing matter of integration and ramp rather than any further winning. This meets all three criteria. (Madden NYC and SM Europe are also new launches/JVs with early/modest contributions and growth ahead, but Schwartz & Benjamin is the clearest fit for the exact timing story.) NO for the other items because they are either not yet live (China JV), not described as partial/early-slice (SM Europe international growth), or not framed as timing-driven ramp (Madden NYC modest contribution is positive but 2018+ profit is more about execution than pure timing). The answer is YES.
AFL · Q2 2023 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the WINGS cancer insurance product launch in Japan Post (early April, during Q2) as a new, nameable contributor that began transacting mid-period. Management explicitly states it was the "majority contributor" to the 60% cancer sales increase in Q2 versus 2022, 26.6% overall sales premium growth, and notes the reported results captured only an early slice because "right when you launch the product, you'll have an immediate jump in sales in the early months followed by a calming down" with "still much more runway...
PDCO · Q3 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes Heartland Dental as a new customer relationship that began contributing in January (during the reported Q3 period), with the rollout completed on schedule and the business now "getting close to being fully operational." Management explicitly notes that this was "not a significant contributor to consumable sales in the third quarter" — confirming the reported results captured only a partial, early slice — while highlighting the "outstanding start" and excitement for further growth as the relationship scales.

More from the question bank

Ecosystem forming: independent outsiders areOperating without a netCall runs ahead of the accountsCustomers eating the frictionBuying its own future outputBetting the balance sheet on one live opportAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.